Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022
Research

Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

Aharona Glatman-FreedmanComments to Author , Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, and Lital Keinan-Boker
Author affiliations: Tel Aviv University School of Public Health, Tel Aviv, Israel (A. Glatman-Freedman, M. Bromberg); Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (A. Glatman-Freedman, M. Bromberg, Y. Hershkovitz, H. Sefty, Z. Kaufman, R. Dichtiar, L. Keinan-Boker); Haifa University School of Public Health, Haifa, Israel (L. Keinan-Boker)

Main Article

Table 2

Rate reduction of severe or critical disease among SARS-CoV-2–positive persons who received the BNT162b2 COVID-19 vaccine booster dose, Israel*

Age group, y Time of first positive
SARS-CoV-2 PCR test after index date, wk		 Unvaccinated SARS-CoV-2–positive persons
 Vaccinated SARS-CoV-2–positive persons
 Adjusted 1 – IRR, % (95% CI)†
Severe or critical disease Total Severe or critical disease Total
16–59 2 422 22,545 2 1,343 92.0 (70.0–97.9)
3 358 18,232 0 455 100.0
4 262 12,962 0 293 100.0
5 170 8,555 0 210 100.0
6 113 5,531 0 138 100.0
7 63 3,573 0 131 100.0
8 40 2,626 0 83 100.0
9 32 2,013 0 54 100.0
10 27 1,714 0 57 100.0
11 29 1,401 0 66 100.0
12 24 1,385 0 90 100.0
13 25 1,442 0 118 100.0
14 21 1,569 0 154 100.0
15 30 2,145 0 351 100.0
16 30 4,088 0 884 100.0
2–16 combined
 727
 41,135
2
 4,427
 97.3 (89.7–99.3)
>60 2 450 1,985 56 1,314 81.9 (75.4–86.7)
3 470 2,200 27 464 73.5 (61.0–82.0)
4 464 2,160 18 375 77.8 (63.1–86.8)
5 469 2,164 15 319 78.9 (66.8–86.6)
6 447 2,033 9 296 86.6 (74.2–93.0)
7 390 1,724 12 271 81.4 (63.1–90.6)
8 299 1,276 13 221 75.6 (54.1–87.0)
9 207 869 2 147 94.6 (85.3–98.0)
10 128 577 9 86 58.6 (11.1–80.7)
11 78 376 2 63 86.2 (39.1–96.9)
12 52 258 3 44 69.0 (−15.3 to 91.7)
13 40 208 1 52 91.0 (63.8–97.8)
14 42 183 2 49 84.0 (44.8–95.3)
15 45 170 3 47 78.5 (49.3–90.8)
16 37 162 3 44 70.3 (30.0–87.4)
17 32 151 1 56 91.7 (43.4–98.8)
18 28 147 0 69 100.0
19 33 184 4 125 83.6 (47.0–94.9)
20 42 305 7 432 89.0 (75.8–95.0)
2–20 combined 1,465 6,673 187 4,474 81.6 (78.3–84.3)

*COVID-19, coronavirus disease; IRR, incidence rate ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Adjusted for sex and epidemiologic week.

Main Article

Page created: March 18, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external